Technical Analysis for APRE - Aprea Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Gapped Up | Strength | -1.07% | |
| Down 3 Days in a Row | Weakness | -1.07% | |
| Down 4 Days in a Row | Weakness | -1.07% | |
| Gapped Up | Strength | -1.74% | |
| Down 3 Days in a Row | Weakness | -1.74% | |
| Narrow Range Bar | Range Contraction | -3.42% | |
| Gapped Down | Weakness | -3.42% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | -5.05% | |
| NR7 | Range Contraction | -5.05% | |
| NR7-2 | Range Contraction | -5.05% |
| Alert | Time |
|---|---|
| Down 1% | 20 minutes ago |
| 60 Minute Opening Range Breakdown | about 21 hours ago |
| 10 DMA Resistance | about 21 hours ago |
| Reversed from Up | about 21 hours ago |
| Gap Up Closed | about 24 hours ago |
Get a Trading Sidekick!
- Earnings date: 05/13/2024
Aprea Therapeutics, Inc. Description
Aprea Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of novel anticancer compounds that reactivate the tumor suppressor protein, p53. The company's lead drug candidate APR-246, a small molecule p53 reactivator, is in clinical development for myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), as well as additional hematologic and solid tumor malignancies. It has commenced a Phase 3 clinical trial in p53 mutant MDS and completed enrollment in a Phase 1b/2 clinical trial in p53 mutant MDS and AML with APR-246 and azacitidine; and additional Phase 1/2 trials of APR-246 in MDS and AML in combination with approved anti-cancer therapies, as well as developing next generation p53 reactivators. The company was founded in 2003 and is based in Boston, Massachusetts.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Clinical Development Tumor Acute Myeloid Leukemia Cancer Therapies Myelodysplastic Syndrome Syndromes P53 Tumor Suppressor Genes Anti Cancer Therapies Tumor Suppressor
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 8.8465 |
| 52 Week Low | 2.78 |
| Average Volume | 34,940 |
| 200-Day Moving Average | 4.88 |
| 50-Day Moving Average | 6.17 |
| 20-Day Moving Average | 5.40 |
| 10-Day Moving Average | 5.23 |
| Average True Range | 0.34 |
| RSI (14) | 40.12 |
| ADX | 29.87 |
| +DI | 11.77 |
| -DI | 23.93 |
| Chandelier Exit (Long, 3 ATRs) | 5.28 |
| Chandelier Exit (Short, 3 ATRs) | 5.93 |
| Upper Bollinger Bands | 5.95 |
| Lower Bollinger Band | 4.86 |
| Percent B (%b) | 0.25 |
| BandWidth | 20.20 |
| MACD Line | -0.25 |
| MACD Signal Line | -0.27 |
| MACD Histogram | 0.019 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 5.51 | ||||
| Resistance 3 (R3) | 5.53 | 5.41 | 5.45 | ||
| Resistance 2 (R2) | 5.41 | 5.32 | 5.41 | 5.43 | |
| Resistance 1 (R1) | 5.27 | 5.26 | 5.22 | 5.26 | 5.41 |
| Pivot Point | 5.16 | 5.16 | 5.13 | 5.15 | 5.16 |
| Support 1 (S1) | 5.02 | 5.07 | 4.97 | 5.01 | 4.86 |
| Support 2 (S2) | 4.91 | 5.01 | 4.90 | 4.84 | |
| Support 3 (S3) | 4.77 | 4.91 | 4.82 | ||
| Support 4 (S4) | 4.76 |
